Hospital Volume Linked to Odds of Appropriate Breast Cancer Locoregional Treatment

Share this content:
Hospital Volume Linked to Odds of Appropriate Breast Cancer Locoregional Treatment
Hospital Volume Linked to Odds of Appropriate Breast Cancer Locoregional Treatment

Hospital volume was significantly associated with processes of breast cancer care measures addressing diagnosis and treatment, a study published in the journal Cancer has shown.1

Variations in delivery of several breast cancer processes of care may be associated with reduced survival and a higher risk of disease recurrence.

To determine the extent to which hospital volume explains this variation, researchers analyzed data from 573,571 women with stage I to III unilateral breast cancer who were treated at 1755 different hospitals between 2007 and 2011. Of those, 38%, 51%, and 10% were treated at high-volume, medium-volume, and low-volume hospitals, respectively.

After controlling for sociodemographic characteristics, treatment year, and geographic location, results showed that hospital volume was significantly predictive for cancer diagnosis by initial biopsy, negative surgical margins, and appropriate locoregional treatment.

Researchers found that patients treated at high-volume hospitals were 30% (odds ratio [OR], 1.30; 95% CI, 1.14-1.49) more likely to have their diagnosis made on initial biopsy compared with those treated at low-volume hospitals.

In addition, patients who received care at high-volume facilities had a 28% (OR, 1.28; 95% CI, 1.13-1.44) higher likelihood of having negative surgical margins and a 16% (OR, 1.16; 95% CI, 1.09-1.24) higher odds of receiving the appropriate locoregional treatment.

The findings suggest that employing these processes to a broader group of hospitals could potentially improve the overall quality of care and outcomes of patients with breast cancer.


1. Yen TW, Pezzin LE, Li J, Sparapani R, Laud PW, Nattinger AB. Effect of hospital volume on processes of breast cancer care: a National Cancer Data Base study. Cancer. 2016 Nov 8. doi: 10.1002/cncr.30413. [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs